Investor Presentaiton
Drive Greater Speed and Efficiency
Evolve into a "data-first, technology-driven" scientific organization
Leverage our scalable operating model and digital enterprise, and optimize cost
structure to drive greater productivity
Committed to operating margin improvement averaging ~50 bps per year beyond 2023
Maintain the "gold standard" for outsourced drug development by adopting key.
technologies and optimizing processes
Accelerate timelines around safety assessment studies, integrated drug development
projects, C> projects, and microbial contamination testing
Enhance speed and execution with seamless access to real-time client data,
data-driven insights, and leveraging scientific and operational data
Multiple efforts to digitalize additional client-facing functions, including RMS e-commerce
solutions and recent launch of Apollo TM for Safety Assessment
Charles River Laboratories (CRL)
1
TEM
Hannah
0
charles riv
222
22View entire presentation